Companies
IQVIA
the largest commercialization partner for named-patient and patient-support programs, drawing on data from more than 5,000 supported launches and the LAAD dataset; on 13 May 2026 it expanded its AI-enabled biosimilar collaboration with Kexing Biopharm (688136.SH) spanning clinical,…
- Country
- United States
- Ticker
- NYSE: IQV
us
psp
ai
Coverage
| CN | EU | US | |
|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ |
Regulatorsfdaefsaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headquarters | Durham, North Carolina, United States | umbrex.com |
| Headcount | approximately 93,000 employees | ir.iqvia.com · iqvia.com · sec.gov |
| Revenue | $16.31 billion in 2025 | ir.iqvia.com |
| Certification | GCLP, GLP, AAALAC, CCAC, OLAW, and BBL (location specific) | labs.iqvia.com |
| Production site | Various global laboratory locations including Durham, NC; Indianapolis, IN; Ithaca, NY; Valencia, CA; Marietta, GA; Laval, Quebec; Marburg, Germany; and Beijing, China medium confidence | labs.iqvia.com |
Independent sources: sec.gov · umbrex.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Medical-affairs platforms (CME, MSL) | market-access-commercial | Low | → |
| Named-patient programs & compassionate use | market-access-commercial | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.